U.S. markets close in 1 hour 57 minutes
  • S&P 500

    4,289.16
    -16.04 (-0.37%)
     
  • Dow 30

    34,090.22
    -61.79 (-0.18%)
     
  • Nasdaq

    12,994.15
    -108.40 (-0.83%)
     
  • Russell 2000

    1,988.15
    -32.38 (-1.60%)
     
  • Crude Oil

    87.96
    +1.43 (+1.65%)
     
  • Gold

    1,776.30
    -13.40 (-0.75%)
     
  • Silver

    19.75
    -0.34 (-1.69%)
     
  • EUR/USD

    1.0197
    +0.0026 (+0.25%)
     
  • 10-Yr Bond

    2.9060
    +0.0820 (+2.90%)
     
  • GBP/USD

    1.2075
    -0.0019 (-0.16%)
     
  • USD/JPY

    134.9610
    +0.7460 (+0.56%)
     
  • BTC-USD

    23,457.35
    -408.26 (-1.71%)
     
  • CMC Crypto 200

    557.93
    -14.89 (-2.60%)
     
  • FTSE 100

    7,515.75
    -20.31 (-0.27%)
     
  • Nikkei 225

    29,222.77
    +353.86 (+1.23%)
     

Pre-clinical findings support the potential use of RhoVac's drug candidate, onilcamotide, across several cancers

·2 min read

STOCKHOLM, May 18, 2022 /PRNewswire/ -- RhoVac AB ("RHOVAC") today, 18th May 2022, announces preclinical findings from its collaboration with St. John's Research Institute (SJRI), a unit of CBCI Society for Medical Education, in Bangalore India. These findings support the hypothesised tissue agnostic mode of action of onilcamotide. The findings identify the crucial MHC-II expression in more tumour cells than was previously known, and they also show co-localisation of the MHC-II receptors and onilcamotide's target protein, RhoC.

In order for a T-cell based cancer vaccine to work, it must be able to induce T cell recognition and elimination of cells expressing one or several target proteins (antigens). These are typically presented by the cells either via receptors called MHC-I or MHC-II. RhoVac's cancer vaccine candidate, onilcamotide, is predominantly driven by T cells of the CD4+ sub-type, and these cells require the antigen to be presented by MHC-II receptors. The pre-clinical study collaboration with Dr Sweta Srivastava, a faculty within St. Johns National Academy of Health Sciences (St. John's Research Institute), CBCI, has now shown that these types of receptors (MHC-II) are found in many different forms of cancer cells, and that RhoC appears to be co-located with these receptors on the cell surface. The data suggests that onilcamotide is tissue agnostic, i.e., that it could be used across cancer types. The data has even documented the presence of MHC-II receptors in more types of cancer than previously known. Fore reference, please find a first article on the findings here: https://www.biorxiv.org/content/10.1101/2022.05.15.492002v1.full.pdf.

RhoVac CEO, Anders Månsson, comments: "We are very excited about these findings that coincide with previous pre-clinical findings suggesting a potential broad use of onilcamotide in cancer, provided we also get a first clinical proof of concept for its use in prostate cancer. If this also comes true - and we will find out soon - our drug candidate has a huge possibility of being used in many different cancers going forward."

This disclosure contains information that RhoVac is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 18-05-2022 18:11 CET.

CONTACT:

For more information, please contact:
Anders Månsson - CEO, RhoVac AB
Phone: +46 73 751 7278
E-mail: info@rhovac.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/rhovac/r/pre-clinical-findings-support-the-potential-use-of-rhovac-s-drug-candidate--onilcamotide--across-sev,c3569855

The following files are available for download: